Inhibiting CGRP in migraine prophylaxis

 

SPECIAL REPORT

Click here to take our survey

60th Annual Scientific Meeting of the American Headache Society, San Francisco CA, 29 June – 1 July 2018 – Erenumab, the first in a new class of monoclonal antibodies that inhibit calcitonin gene-related peptide (CGRP), has now been approved in the U.S. Other agents in development are fremanezumab, eptinezumab and galcanezumab. The following is a summary of new data on these agents presented at the 60th annual meeting of the American Headache Society.

It takes 30 seconds

SURVEY

This poll is currently disabled.

Recommend to a Colleague

Related Posts

Go back to home page